查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1396614

2030年全球奈米抗體市場預測

Nanobody Market Research Report Forecast till 2030
出版日期: | 出版商: Market Research Future | 英文 128 Pages | 訂單完成後即時交付

價格

全球奈米抗體市場規模預計在預測期內將以 17.88% 的複合年增長率大幅擴張。 慢性病的流行、對精準醫療的興趣日益濃厚以及對奈米抗體研究的興趣不斷擴大正在推動市場成長。

區域考慮

2022年北美市場佔最大市場份額。

歐洲市場佔第二大市場。 德國市場佔有最大的市場份額，法國市場是歐洲成長最快的。

從 2023 年到 2030 年，亞太市場預計將成長到巨大份額。

本報告研究分析全球奈米抗體市場，提供市場動態、區域和細分市場分析、公司簡介等。

目錄

第 1 章執行摘要

第二章市場介紹

第三章研究方法

第 4 章市場動態

  • 摘要
  • 促進因素
    • 慢性病流行
    • 對精準醫療的需求不斷增加
    • 增加奈米抗體研發的投資
  • 抑制因素
    • 製造挑戰與高生產成本
  • 機會
    • 擴大奈米抗體新應用的開發

第五章市場因素分析

  • 價值鏈分析
    • 研究與開發
    • 製造業
    • 分銷/銷售
    • 售後監控
  • 波特五力分析模型
  • COVID-19 對全球奈米抗體市場的影響
    • 對供應鏈的影響
    • 對臨床試驗的影響
    • 對供需的影響

第 6 章全球奈米抗體市場：依類型

  • 摘要
  • 單一特異性
  • 多具體

第七章全球奈米抗體市場：依應用分類

  • 摘要
  • 治療
    • 癌症
    • 神經退化性疾病
    • 傳染病
    • 其他
  • 診斷
    • 蛋白質和微生物檢測
    • 小分子檢測
    • 成像
  • 研究

第 8 章全球奈米抗體市場：依最終用戶劃分

  • 摘要
  • 製藥公司、生技公司
  • 實驗室
  • 其他

第 9 章全球奈米抗體市場：按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 亞太地區其他地區
  • 其他領域
    • 中東
    • 非洲
    • 拉丁美洲

第10章競爭態勢

  • 摘要
  • 競爭基準測試
  • 全球奈米抗體市場的主要成長策略
  • 全球奈米抗體市場的主要公司（按開發數量）
  • 主要進展分析
  • 主要發展與成長策略
    • 產品發布/產品核准
    • 併購
    • 合作夥伴關係/協議/隸屬關係
  • 主要企業銷售分析
  • 主要企業研發分析

第十一章公司簡介

  • SANOFI
  • MERCK KGAA
  • BIOCYTOGEN
  • PROTEINTECH GROUP, INC.
  • NOVARTIS AG
  • GENSCRIPT
  • SENSEI BIOTHERAPEUTICS, INC
  • BERONI GROUP
  • EXEVIR BIO
  • TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
  • DIOSCURE THERAPEUTICS SE

第12章附錄

Product Code: MRFR/HC/9539-CR

Market Overview

Nanobody Market is anticipated to register a significant market expansion at a CAGR of 17.88% during the forecast period. The rising pervasiveness of constant sicknesses, rising interest for accuracy medication, and expanding interest in nanobody innovative work are driving market development.

Nanobodies are little immunizer sections that enjoy a few upper hands over conventional antibodies, like more prominent dependability, better tissue entrance, and decreased immunogenicity. The rising commonness of immune system infections and other ongoing issues requests the revelation of fresher and more compelling nanobody-based drugs for their treatment. For example, in February 2019, the US Food and Medication Organization (FDA) endorsed Cablivi (caplacizumab-yhdp), the main nanobody-based medication of Sanofi S.A. (France), for grown-ups with gained thrombotic thrombocytopenic purpura (aTTP).

As indicated by the World Wellbeing Association (WHO), constant infections like malignant growth, cardiovascular sickness, and diabetes are answerable for 74% of all passings universally. The occurrence and predominance of these illnesses are supposed to keep on rising, driven by elements like maturing populaces, evolving ways of life, and expanding urbanization. Subsequently, the rising commonness of persistent infections, joined with the extraordinary benefits of nanobodies drives the market development.

Market Segmentation

Based on type the Nanobody Market is bifurcated into mono-specific and multi-specific. Based on application the market is divided into therapeutic, diagnostic, and research. The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others. The Nanobody Market based on end user is classified into pharmaceutical & biotechnology companies, research laboratories, and others.

Regional Insights

The North America nanobody market represented the biggest market share in 2022. This is because of the great mindfulness related with nanobodies innovation in drug revelation and advancement to diminish the expense of creation in the North American area.

Europe nanobody market represents the second-biggest market share because of the presence of dynamic market players, developing nanobodies new businesses, and expanding predominance of illnesses, for example, irresistible, neurological, and disease. further, Germany nanobody market was ascribed to hold the biggest market share, and the France nanobody market is supposed to quickest developing market in the European locale.

The Asia-Pacific nanobody market is supposed to develop at a huge share from 2023 to 2030. This is because of the developing geriatric populace, expanding predominance of malignant growth and irresistible sicknesses, and further developing examination abilities in the Asia-Pacific locale.

The Remainder of the World is sectioned into the Center East, Africa, and Latin America. The nanobody market in the previously mentioned locales is probably going to observe development because of the rising pervasiveness of irresistible illnesses and the rising predominance of non-transferable sicknesses.

Major Players

Key Companies in the Nanobody Market include Sanofi (France), Merck KGaA (Germany), BIOCYTOGEN (US), Proteintech Group, Inc (US), Novartis AG (Switzerland), GenScript (US), Sensei Biotherapeutics, Inc (US), Beroni Group (Australia), ExeVir Bio (Belgium), Taisho Pharmaceutical Holdings Co., Ltd (Japan), and DiosCURE Therapeutics SE (Germany).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
    • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.4 FORECASTING TECHNIQUES
  • 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.5.1 BOTTOM-UP APPROACH
    • 3.5.2 TOP-DOWN APPROACH
  • 3.6 DATA TRIANGULATION
  • 3.7 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES
    • 4.2.2 RISING DEMAND FOR PRECISION MEDICINE
    • 4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT
  • 4.3 RESTRAINTS
    • 4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS
  • 4.4 OPPORTUNITY
    • 4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON CLINICAL TRIALS
    • 5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL NANOBODY MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 MONO-SPECIFIC
  • 6.3 MULTI-SPECIFIC

7 GLOBAL NANOBODY MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 THERAPEUTIC
    • 7.2.1 CANCER
    • 7.2.2 NEURODEGENERATIVE DISEASES
    • 7.2.3 INFECTIOUS DISEASES
    • 7.2.4 OTHERS
  • 7.3 DIAGNOSTIC
    • 7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS
    • 7.3.2 DETECTION OF SMALL MOLECULES
    • 7.3.3 IMAGING
  • 7.4 RESEARCH

8 GLOBAL NANOBODY MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.3 RESEARCH LABORATORIES
  • 8.4 OTHERS

9 GLOBAL NANOBODY MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 UK
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 SOUTH KOREA
    • 9.4.5 AUSTRALIA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET
  • 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET
  • 10.5 KEY DEVELOPMENT ANALYSIS
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
    • 10.6.2 MERGER/ ACQUISITION
    • 10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION
  • 10.7 MAJOR PLAYERS SALES ANALYSIS
  • 10.8 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

  • 11.1 SANOFI
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 MERCK KGAA
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 BIOCYTOGEN
    • 11.3.1 COMPANY OVERVIEWS
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 PROTEINTECH GROUP, INC.
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 KEY STRATEGIES
  • 11.5 NOVARTIS AG
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTSS
    • 11.5.5 SWOT ANALYSIS
    • 11.5.6 KEY STRATEGIES
  • 11.6 GENSCRIPT
    • 11.6.1 COMPANY OVERVIEWS
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 SENSEI BIOTHERAPEUTICS, INC
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
    • 11.7.6 KEY STRATEGIES
  • 11.8 BERONI GROUP
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 EXEVIR BIO
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGIES
  • 11.11 DIOSCURE THERAPEUTICS SE
    • 11.11.1 COMPANY OVERVIEW
    • 11.11.2 FINANCIAL OVERVIEW
    • 11.11.3 PRODUCTS OFFERED
    • 11.11.4 KEY DEVELOPMENTS
    • 11.11.5 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 GLOBAL NANOBDOY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 3 GLOBAL NANOBDOY MARKET, FOR MONO-SPECIFIC, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 4 GLOBAL NANOBDOY MARKET, FOR MULTI-SPECIFIC, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 5 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 6 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 7 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 8 GLOBAL NANOBDOY MARKET, FOR CANCER, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 9 GLOBAL NANOBDOY MARKET, FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 10 GLOBAL NANOBDOY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 11 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 12 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 13 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 14 GLOBAL NANOBDOY MARKET, FOR DETECTION OF PROTEINS AND MICROORGANISMS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 15 GLOBAL NANOBDOY MARKET, FOR DETECTION OF SMALL MOLECULES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 16 GLOBAL NANOBDOY MARKET, FOR IMAGING, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 17 GLOBAL NANOBDOY MARKET, FOR RESEARCH, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 18 GLOBAL NANOBDOY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 19 GLOBAL NANOBDOY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 20 GLOBAL NANOBDOY MARKET, FOR RESEARCH LABORATORIES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 21 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 22 GLOBAL: NANOBODY MARKET, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 23 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 24 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 25 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 26 NORTH AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 27 NORTH AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 28 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 29 US: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 30 US: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 31 US: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 32 US: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 33 US: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 34 CANADA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 35 CANADA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 36 CANADA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 37 CANADA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 38 CANADA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 39 EUROPE: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 40 EUROPE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 41 EUROPE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 42 EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 43 EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 44 EUROPE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 45 GERMANY: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 46 GERMANY: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 47 GERMANY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 48 GERMANY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 49 GERMANY: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 50 UK: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 51 UK: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 52 UK: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 53 UK: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 54 UK: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 55 FRANCE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 56 FRANCE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 57 FRANCE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 58 FRANCE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 59 FRANCE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 60 ITALY: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 61 ITALY: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 62 ITALY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 63 ITALY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 64 ITALY: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 65 SPAIN: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 66 SPAIN: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 67 SPAIN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 68 SPAIN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 69 SPAIN: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 70 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 71 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 72 REST OF EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 73 REST OF EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 74 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 75 ASIA PACIFIC: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 76 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 77 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 78 ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 79 ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 80 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 81 JAPAN: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 82 JAPAN: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 83 JAPAN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 84 JAPAN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 85 JAPAN: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 86 CHINA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 87 CHINA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 88 CHINA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 89 CHINA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 90 CHINA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 91 INDIA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 92 INDIA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 93 INDIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 94 INDIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 95 INDIA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 96 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 97 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 98 SOUTH KOREA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 99 SOUTH KOREA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 100 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 101 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 102 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 103 AUSTRALIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 104 AUSTRALIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 105 AUSTRALIA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 106 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 107 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 108 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 109 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 110 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 111 REST OF THE WORLD: NANOBODY MARKET, BY REGION, 2019-2030(USD BILLION)
  • TABLE 112 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 113 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 114 REST OF THE WORLD: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 115 REST OF THE WORLD: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 116 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 117 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 118 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 119 MIDDLE EAST: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 120 MIDDLE EAST: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 121 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 122 AFRICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 123 AFRICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 124 AFRICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 125 AFRICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 126 AFRICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 127 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 128 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2019-2030 (USD BILLION)
  • TABLE 129 LATIN AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 130 LATIN AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2030 (USD BILLION)
  • TABLE 131 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2019-2030 (USD BILLION)
  • TABLE 132 MAJOR PLAYERS IN THE GLOBAL NANOBODY MARKET
  • TABLE 133 MOST ACTIVE PLAYER IN THE GLOBAL NANOBODY MARKET
  • TABLE 134 PRODUCT LAUNCH/PRODUCT APPROVAL
  • TABLE 135 MERGER/ ACQUISITION
  • TABLE 136 PARTNERSHIP/ AGREEMENT/COLLABORATION
  • TABLE 137 SANOFI: PRODUCTS OFFERED
  • TABLE 138 SANOFI: KEY DEVELOPMENTS
  • TABLE 139 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 140 MERCK KGAA: KEY DEVELOPMENTS
  • TABLE 141 BIOCYTOGEN: PRODUCTS OFFERED
  • TABLE 142 BIOCYTOGEN: KEY DEVELOPMENTS
  • TABLE 143 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
  • TABLE 144 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 145 GENSCRIPT: PRODUCTS OFFERED
  • TABLE 146 SENSEI BIOTHERAPEUTICS: PRODUCTS OFFERED
  • TABLE 147 SENSEI BIOTHERAPEUTICS: KEY DEVELOPMENTS
  • TABLE 148 BERONI GROUP: PRODUCTS OFFERED
  • TABLE 149 BERONI GROUP: KEY DEVELOPMENTS
  • TABLE 150 EXEVIR BIO BV.: PRODUCTS OFFERED
  • TABLE 151 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: PRODUCTS OFFERED
  • TABLE 152 DIOSCURE THERAPEUTICS SE: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL NANOBODY MARKET STRUCTURE
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: GLOBAL NANOBODY MARKET
  • FIGURE 5 DRIVER IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL NANOBODY MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NANOBODY MARKET
  • FIGURE 9 GLOBAL NANOBODY MARKET, TYPE SEGMENT ATTRACTIVENESS, (USD BILLION)
  • FIGURE 10 GLOBAL NANOBDOY MARKET, BY TYPE, 2022 & 2030 (USD BILLION)
  • FIGURE 11 GLOBAL NANOBDOY MARKET SHARE (%), BY TYPE, 2022
  • FIGURE 12 GLOBAL NANOBODY MARKET, APPLICATION SEGMENT ATTRACTIVENESS, (USD BILLION)
  • FIGURE 13 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2022 & 2030 (USD BILLION)
  • FIGURE 14 GLOBAL NANOBDOY MARKET SHARE (%), BY APPLICATION, 2022
  • FIGURE 15 GLOBAL NANOBODY MARKET, END USER SEGMENT ATTRACTIVENESS, (USD BILLION)
  • FIGURE 16 GLOBAL NANOBDOY MARKET, BY END USER, 2022 & 2030 (USD BILLION)
  • FIGURE 17 GLOBAL NANOBDOY MARKET SHARE (%), BY END USER, 2022
  • FIGURE 18 GLOBAL: NANOBODY MARKET, BY REGION 2022 & 2030 (USD BILLION)
  • FIGURE 19 GLOBAL: NANOBODY MARKET SHARE (%), BY REGION, 2022
  • FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
  • FIGURE 21 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY 2022 & 2030 (USD BILLION)
  • FIGURE 22 NORTH AMERICA: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
  • FIGURE 23 EUROPE MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
  • FIGURE 24 EUROPE: NANOBODY MARKET, BY COUNTRY 2022 & 2030 (USD BILLION)
  • FIGURE 25 EUROPE: NANOBODY MARKET SHARE (%), BY COUNTRY 2022
  • FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
  • FIGURE 27 ASIA PACIFIC NANOBODY MARKET SHARE, BY COUNTRY 2022 & 2030 (USD BILLION)
  • FIGURE 28 ASIA PACIFIC: NANOBODY MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOBODY MARKET, 2019-2030 (USD BILLION)
  • FIGURE 30 REST OF THE WORLD NANOBODY MARKET SHARE, BY REGION 2022 & 2030 (USD BILLION)
  • FIGURE 31 REST OF THE WORLD: NANOBODY MARKET SHARE (%), BY REGION, 2022
  • FIGURE 32 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 33 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL NANOBODY MARKET
  • FIGURE 34 GLOBAL NANOBODY MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 35 MAJOR PLAYERS SALES, 2022 (USD BILLION)
  • FIGURE 36 MAJOR PLAYER R&D EXPENDITURE, 2022 (USD BILLION)
  • FIGURE 37 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 SANOFI: SWOT ANALYSIS
  • FIGURE 39 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 MERCK KGAA: SWOT ANALYSIS
  • FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 42 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 43 GENSCRIPT: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 44 GENSCRIPT: SWOT ANALYSIS
  • FIGURE 45 SENSEI BIOTHERAPEUTICS: SWOT ANALYSIS
  • FIGURE 46 BERONI GROUP: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 47 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: FINANCIAL OVERVIEW SNAPSHOT